Ossifying Renal Tumor of Infancy (ORTI) is an extremely uncommon, non-cancerous kidney tumor seen in babies, noted for its unique tissue features. Protheragen's comprehensive capabilities enable us to support preclinical diagnostics and therapeutics development for rare pediatric tumors such as ORTI.
Overview of Ossifying Renal Tumor of Infancy (ORTI)
Ossifying renal tumor of infancy (ORTI) is an uncommon, non-cancerous kidney growth seen in babies, first reported back in 1980. It shows a strong bend toward very young infants, usually those younger than twelve months, with the average child diagnosed around four-and-a-half months, and boys outnumber girls. When doctors look at ORTI cases, they often hear about bright red blood in the urine or, less frequently, a soft lump in the belly. Under the microscope, the tumor shows three main parts inner area that looks like bone (osteoid), cells that act like bone builders (osteoblast-like), and long, thin fibers (spindle cells). Even though ORTI is not cancer, careful tests must be done to tell it apart from worse tumors like Wilms' tumor because the scans can look almost the same.
Fig.1 A case of ultrasonography and pathological analysis of ossifying renal tumor of infancy (ORTI). (Kasai S.,
et al., 2024)
Pathogenesis of Ossifying Renal Tumor of Infancy (ORTI)
Researchers still struggle to pin down exactly how ORTI forms, yet a few competing ideas keep coming up. One line of thought argues that the tumor might start in the urothelium itself, since those cells seem capable of turning into bone-like tissue. Another possibility points to intralobar nephrogenic rests (ILNR); the spindle-shaped cells seen in ORTI look a lot like the ones found in those perfectly healthy kidney nests. On a genetic level, newly spotted changes like a CTNNB1 mutation could be key; this alteration affects the -catenin protein and sends it into the cell nucleus. Once there, extra-catenin pushes the cell to divide and mature faster than normal. Because of that link, scientists think the CTNNB1 shift might mark an important step in ORTI's rise and deserves deeper study.
Diagnostics Development for Ossifying Renal Tumor of Infancy (ORTI)
Imaging-Based Diagnostics
- Ultrasound: Often the initial imaging modality used to detect renal masses in infants. ORTI typically presents as a hypoechoic mass with shadowing due to calcification.
- Computed Tomography (CT): Provides detailed anatomical information, showing a well-defined mass with calcification and poor enhancement. CT is useful for surgical planning.
- Magnetic Resonance Imaging (MRI): Offers superior soft tissue contrast, with ORTI masses exhibiting low T2 signal intensity, aiding in differentiation from other renal tumors.
Molecular and Genetic Diagnostics
- Whole Exome Sequencing (WES): Enables the identification of genetic alterations, such as the CTNNB1 mutation, which was recently identified in ORTI. WES can provide insights into the molecular pathogenesis of ORTI.
- Copy Number Variation (CNV) Analysis: Detects genomic imbalances, such as gains or losses of specific loci, which may contribute to ORTI tumorigenesis.
Therapeutics Development for Ossifying Renal Tumor of Infancy (ORTI)
- Targeted Therapies: Given the identification of genetic alterations like CTNNB1 mutations, targeted therapies aimed at inhibiting β-catenin signaling pathways may hold promise for ORTI therapy.
- Immunotherapy: Although not currently standard for ORTI, immunotherapeutic approaches could be explored, particularly for cases with aggressive features or recurrence.
Table 1. Therapeutics of Ossifying Renal Tumor of Infancy (ORTI).
| Therapeutics |
Drug Name |
Mechanism |
Description |
Stage |
| Surgical Intervention |
Partial Nephrectomy |
Physical tumor removal |
Preferred for localized tumors to preserve renal function; curative in benign cases. |
Approved |
| Surgical Intervention |
Radical Nephrectomy |
Complete kidney removal |
Reserved for large or technically unresectable tumors; definitive therapeutic. |
Approved |
| Targeted Therapy |
PRI-724 (β-catenin inhibitor) |
Blocks β-catenin/TCF signaling |
Targets the CTNNB1 mutation-driven pathway; under investigation for ORTI. |
Preclinical |
| Targeted Therapy |
LGK974 (Porcupine inhibitor) |
Inhibits Wnt ligand secretion |
Disrupts Wnt/β-catenin pathway activation; potential for CTNNB1-mutated tumors. |
Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen provides a wide range of services for ORTI diagnostics and therapeutics development, including imaging-based diagnostics, molecular and genetic diagnostics, and emerging therapeutic approaches. Our services are designed to support the entire drug development pipeline, from discovery to preclinical studies, ensuring clients have access to the resources and expertise needed to advance the development of ORTI therapies.
Disease Models
- Syngeneic (Allograft) Models in Rodents
- Genetically Engineered Mouse (GEM) Models
- Chemically-induced Renal Tumor Models
- Patient-derived Xenograft (PDX) Models in Immunodeficient Mice
Protheragen's preclinical research services for ORTI include in vitro and in vivo models, molecular and genetic analyses, and pharmacokinetic and pharmacodynamic studies. These services are designed to elucidate the underlying mechanisms of ORTI, identify novel therapeutic targets, and evaluate the efficacy and safety of potential therapeutics. If you are interested in our services, please feel free to contact us.
References
- Kasai, Shin, et al. "In utero tumor development and identification of CTNNB1 mutation in a newborn case of ossifying renal tumor of infancy." Pediatric blood & cancer 71.4 (2024): e30868.
- Flannigan, Ryan Kendrick, et al. "Case report and literature review of a rare diagnosis of ossifying renal tumour of infancy." Canadian Urological Association Journal 8.3-4 (2014): E184.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
